Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1115 details
Primary information
ID10564
Therapeutic IDTh1115
Protein NameTeicoplanin
SequenceNA
Molecular Weight1879.658
Chemical FormulaC88H97Cl2N9O33
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-life70-100 hrs
DescriptionGlycopeptide antibiotic. It is a mixture of several compounds majorly teicoplanin A2-1 through A2-5, along with four minor ones, teicoplanin RS-1 through RS-4. They all share a same glycopeptide core, referred to as teicoplanin A3-1, which is a fused ring structure bound by two carbohydrates (mannose and N-acetylglucosamine). The components also contain a third carbohydrate moiety, β-D-glucosamine, and differ only by the length and conformation of a side chain attached to it.
Indication/DiseaseFor the treatment of bacterial infections caused by susceptible microorganisms.
PharmacodynamicsTeicoplanin is an antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin.
Mechanism of ActionTeicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAnti-Bacterial Agents
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan
Brand NameTargocid
CompanyNPS Pharmaceuticals
Brand DescriptionNPS Pharmaceuticals
Prescribed ForActs against Gram-postive bacteria including methicillin-resistant Staphylococcus aureus and Enterococcus fecalis. Targocid is indicated in adults and in children from birth for the parenteral treatment of the following infections skin and soft tissue infections, bone and joint infections, hospital acquired pneumonia, community acquired pneumonia, complicated urinary tract infections, infective endocarditis, continuous ambulatory peritoneal dialysis (CAPD), bacteraemia that occurs in association with any of the indications listed above. Targocid is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.
Chemical NameNA
FormulationEach vial of Targocid injection contains 400 mg teicoplanin. The glass vial also contains an inactive ingredient, sodium chloride which is included to minimise stinging and pain when the injection is administered. There are no dyes, gluten or preservatives in Targocid injection.
Physical Appearance Light yellow solid
Route of AdministrationIntramuscular, Intravenous
Recommended DosageNA
ContraindicationSerious, life-threatening hypersensitivity reactions, sometimes fatal, have been reported with teicoplanin (e.g. anaphylactic shock). If an allergic reaction to teicoplanin occurs, treatment should be discontinued immediately and appropriate emergency measures should be initiated. Teicoplanin must be administered with caution in patients with known hypersensitivity to vancomycin, as crossed hypersensitivity reactions, including fatal anaphylactic shock, may occur. However, a prior history of red man syndrome with vancomycin is not a contraindication to the use of teicoplanin.
Side EffectsInfusion related reactions, Severe bullous reactions, Nephrotoxicity, Ototoxicity, Superinfection
Useful Link 1Link
Useful Link 2NA
RemarksNA